Results 271 to 280 of about 546,461 (357)
ABSTRACT This study presents the case of a child with multiple congenital anomalies, severe hypotonia, and profound bilateral sensorineural hearing loss. Functional bioenergetic assessments showed no significant mitochondrial respiratory defects, and riboflavin (Rf) status evaluation excluded a deficiency in Rf transporters as a cause of hearing loss ...
Piero Leone+13 more
wiley +1 more source
Genome Sequencing Uncovers Additional Findings in Phelan‐McDermid Syndrome
ABSTRACT Phelan‐McDermid syndrome (PMS) is a genetic condition caused by deletions of chromosome 22q13.3 or pathogenic variants in the SHANK3 gene. Neurologic features typically include intellectual disability, autism spectrum disorder, hypotonia, and absent speech, though there is considerable variability even among individuals with the same molecular
Rachel Gore Moses+21 more
wiley +1 more source
Role of Computed Tomography Findings in Diagnosing Pulmonary Atresia With Intact Ventricular Septum and Right Ventricle-Dependent Coronary Circulation: A Case Report. [PDF]
Thurmann KE, Richardson RR.
europepmc +1 more source
Papilloma of the Right Laryngeal Ventricle, with Blood Cyst of Vocal Cord
James Atkinson
openalex +1 more source
Impact of Konno Procedure on Right Heart Function. [PDF]
Ganguly P+8 more
europepmc +1 more source
ABSTRACT Turner Syndrome (TS) is a sex chromosomal disorder associated with karyotype heterogeneity. Although TS can be associated with severe prenatal findings, most often linked to the 45, X karyotype, the majority of TS fetuses have no overt phenotype, resulting in delayed diagnosis and management.
Ivonne Bedei+10 more
wiley +1 more source
Clinical Application of 4D Flow Cardiac Magnetic Resonance for Evaluating Complications After Surgical Aortic Valve Prosthesis Implantation. [PDF]
López Alcolea J+9 more
europepmc +1 more source
ABSTRACT Rare diseases impact approximately 1 in 10 people worldwide, and yet, less than 5% of all rare diseases currently have an approved treatment option available. This is due to many challenges unique to rare diseases, including small, diverse patient populations, the cost of drug development that is not proportionate to the number of patients who
Caleb P. Bupp+7 more
wiley +1 more source